Sirtris Pharmaceuticals Presents at Future Leaders in the Biotechnology Industry Conference March 27

  
    
  
  
    
      Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical 
      company focused on discovering and developing small molecule drugs to 
      treat diseases of aging such as Type 2 Diabetes, announced that it will 
      be presenting at the BioCentury/Thomson Financial 15th 
      Annual Future Leaders in the Biotechnology Industry Conference on 
      Thursday, March 27 at 1:30 pm EDT. The presentation will be webcast live 
      and can be accessed on the Sirtris website (www.sirtrispharma.com) 
      in the "Investor Relations" section. A replay will be available after 
      the presentation and will be archived on the company's website for two 
      weeks.
    
    
      In January, Sirtris announced positive Phase 1b clinical trial results 
      with drug candidate SRT501, a proprietary formulation of resveratrol, in 
      patients with Type 2 Diabetes. SRT501, which targets the SIRT1 enzyme, 
      was found to be safe and well-tolerated, and significantly lowered 
      glucose at the two-hour time point in an oral glucose tolerance test 
      conducted as part of the 28 day Phase 1b trial of patients with Type 2 
      Diabetes who were naive to treatment. Sirtris' new chemical entities 
      (NCEs) activate SIRT1 and are chemically distinct from and 1000 times 
      more potent, in vitro, than resveratrol. The NCEs have been shown to 
      lower glucose and improve insulin sensitivity in predictive pre-clinical 
      models of Type 2 Diabetes. SIRT1 activators have the potential to be a 
      frontline therapy for Type 2 Diabetes.
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes that the 
      Company believes control the aging process. The company's headquarters 
      are in Cambridge, Massachusetts.
    
    
      This press release contains forward-looking statements within the 
      meaning of the Private Securities Litigation Reform Act of 1995. Such 
      statements include, but are not limited to, the potential therapeutic 
      effects of SIRT1 activators including NCEs for diseases of aging, such 
      as Type 2 Diabetes: the progress and results of pre-clinical and 
      clinical studies of SIRT1 activators, such as SRT501 and Sirtris’ 
      NCEs; and the potential of sirtuin modulators to receive regulatory 
      approval. These forward-looking statements about future expectations, 
      plans and prospects of Sirtris Pharmaceuticals involve significant 
      risks, uncertainties and assumptions, including risks related to the 
      lack of results that would provide a basis for predicting whether any of 
      the Company's product candidates will be safe or effective, or receive 
      regulatory approval, the possibility that results of pre-clinical 
      studies are not necessarily predictive of clinical trial results, the 
      Company's potential inability to initiate and complete pre-clinical 
      studies and clinical trials for its product candidates, the fact that 
      none of the Company's product candidates has received regulatory 
      approvals, the potential inability of the Company to gain market 
      acceptance of the Company's product candidates, and those other risks 
      factors that can be found in the Company's filings with the Securities 
      and Exchange Commission. Actual results may differ materially from those 
      Sirtris Pharmaceuticals contemplated by these forward-looking 
      statements. Sirtris Pharmaceuticals does not undertake to update any of 
      these forward-looking statements to reflect a change in its views or 
      events or circumstances that occur after the date of this release.